EFFICACY AND SAFETY OF OPEN-LABEL CAPLACIZUMAB IN PATIENTS WITH EXACERBATIONS OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING THE PHASE III HERCULES STUDY

被引：0
|
作者：
Peyvandi, F.
Scully, M.
Cataland, S.
Coppo, P.
Knoebl, P.
Kremer Hovinga, J.
Metjian, A.
de la Rubia, J.
Pavenski, K.
Callewaert, F.
Biswas, D.
De Winter, H.
Zeldin, R. K.
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England
[4] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[5] St Antoine Univ Hosp, Dept Hematol, Paris, France
[6] Vienna Univ Hosp, Div Hematol & Hemostasis, Dept Med 1, Vienna, Austria
[7] Bern Univ Hosp, Univ Clin Hematol, Inselspital, Bern, Switzerland
[8] Bern Univ Hosp, Cent Hematol Lab, Inselspital, Bern, Switzerland
[9] Duke Univ, Sch Med, Div Hematol, Durham, NC USA
[10] Univ Catolica Valencia Hosp Doctor Peset, Hematol Dept, Valencia, Spain
[11] St Michaels Hosp, Dept Lab Med & Pathobiol, Res Inst, Toronto, ON, Canada
[12] Ablynx NV, Clin Dev, Zwijnaarde, Belgium
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO031
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura during the phase III HERCULES study
    Knoebl, P.
    Scully, M.
    Cataland, S.
    Peyvandi, F.
    Coppo, P.
    Hovinga, Kremer J.
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 105 - 105
  • [2] Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
    Knoebl, Paul
    Cataland, Spero
    Peyvandi, Flora
    Coppo, Paul
    Scully, Marie
    Hovinga, Johanna A. Kremer
    Metjian, Ara
    de la Rubia, Javier
    Pavenski, Katerina
    Edou, Jessica Minkue Mi
    De Winter, Hilde
    Callewaert, Filip
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (02) : 479 - 484
  • [3] Caplacizumab for acquired thrombotic thrombocytopenic purpura - results of the phase 3 HERCULES study
    Scully, M.
    Cataland, S.
    Peyvandi, F.
    Coppo, P.
    Knoebl, P.
    Hovinga, J. A. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    de Winter, H.
    Zeldin, R. K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 18 - 18
  • [4] The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
    Miyakawa, Yoshitaka
    Imada, Kazunori
    Ichikawa, Satoshi
    Uchiyama, Hitoji
    Ueda, Yasunori
    Yonezawa, Akihito
    Fujitani, Shigeki
    Ogawa, Yoshiyuki
    Matsushita, Tadashi
    Asakura, Hidesaku
    Nishio, Kenji
    Suzuki, Kodai
    Hashimoto, Yasuhiro
    Murakami, Hidenori
    Tahara, Sayaka
    Tanaka, Tomoyuki
    Matsumoto, Masanori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (03) : 366 - 377
  • [5] The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
    Yoshitaka Miyakawa
    Kazunori Imada
    Satoshi Ichikawa
    Hitoji Uchiyama
    Yasunori Ueda
    Akihito Yonezawa
    Shigeki Fujitani
    Yoshiyuki Ogawa
    Tadashi Matsushita
    Hidesaku Asakura
    Kenji Nishio
    Kodai Suzuki
    Yasuhiro Hashimoto
    Hidenori Murakami
    Sayaka Tahara
    Tomoyuki Tanaka
    Masanori Matsumoto
    International Journal of Hematology, 2023, 117 : 366 - 377
  • [6] The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study
    Miyakawa, Yoshitaka
    Imada, Kazunori
    Ichikawa, Satoshi
    Uchiyama, Hitoji
    Ueda, Yasunori
    Yonezawa, Akihito
    Fujitani, Shigeki
    Handa, Hiroshi
    Matsushita, Tadashi
    Asakura, Hidesaku
    Nishio, Kenji
    Suzuki, Kodai
    Hashimoto, Yasuhiro
    Ohshima, Shinobu
    Tahara, Sayaka
    Tanaka, Tomoyuki
    Matsumoto, Masanori
    BLOOD, 2021, 138
  • [7] Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
    Estcourt, L. J.
    TRANSFUSION MEDICINE, 2019, 29 (03) : 146 - 148
  • [8] Caplacizumab in acquired thrombotic thrombocytopenic Purpura (aTTP): Long-term Safety and Efficacy in the Post-HERCULES Study
    Knoebl, P.
    Scully, M.
    de la Rubia, J.
    Pavenski, K.
    Metjian, A.
    Peyvandi, F.
    Cataland, S.
    Coppo, P.
    Hovinga, Kremer J. A.
    Edou, Minkue Mi J.
    Sousa, De Passos R.
    Callewaert, F.
    Gunawardena, S.
    Lin, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 47 - 47
  • [9] Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study
    Scully, Marie
    la Rubia, Javierde
    Pavenski, Katerina
    Metjian, Ara
    Knoebl, Paul
    Peyvandi, Flora
    Cataland, Spero
    Coppo, Pual
    Strebel, Johanna A. Kremer Hovinga
    Edou, Jessica Minkue Mi
    Sousa, Ruide Passos
    Callewaert, Filip
    Gunawardena, Sriya
    Lin, Julie
    BLOOD, 2021, 138
  • [10] Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
    Maqsood, Muhammad Haisum
    Rubab, Kinza
    Maqsood, Muhammad Zaigham
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
12345